448 related articles for article (PubMed ID: 3455678)
1. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
2. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
4. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission.
Harker WG; Bauer D; Etiz BB; Newman RA; Sikic BI
Cancer Res; 1986 May; 46(5):2369-73. PubMed ID: 3754487
[TBL] [Abstract][Full Text] [Related]
5. Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase.
Beck WT; Cirtain MC
Cancer Res; 1982 Jan; 42(1):184-9. PubMed ID: 7198507
[TBL] [Abstract][Full Text] [Related]
6. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.
Cass CE; Janowska-Wieczorek A; Lynch MA; Sheinin H; Hindenburg AA; Beck WT
Cancer Res; 1989 Nov; 49(21):5798-804. PubMed ID: 2790792
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine.
Conter V; Beck WT
Cancer Treat Rep; 1984 Jun; 68(6):831-9. PubMed ID: 6539648
[TBL] [Abstract][Full Text] [Related]
8. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
[TBL] [Abstract][Full Text] [Related]
9. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
Danks MK; Yalowich JC; Beck WT
Cancer Res; 1987 Mar; 47(5):1297-301. PubMed ID: 3469013
[TBL] [Abstract][Full Text] [Related]
10. Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells.
Zamora JM; Beck WT
Biochem Pharmacol; 1986 Dec; 35(23):4303-10. PubMed ID: 3466591
[TBL] [Abstract][Full Text] [Related]
11. Study of sodium orthovanadate as a reverser of multidrug resistance on lymphoblastic leukemic CEM/VLB100 cells.
Colin M; Madoulet C; Baccard N; Arsac F; Jardillier JC
Anticancer Res; 1994; 14(6A):2383-7. PubMed ID: 7825977
[TBL] [Abstract][Full Text] [Related]
12. Cross-resistance patterns and antigen expression in Vinca alkaloid- and other multiple drug-resistant human leukemic cell lines.
Beck WT; Danks MK; Cirtain MC; van Heiningen JN
Prog Clin Biol Res; 1986; 223():3-10. PubMed ID: 3468517
[TBL] [Abstract][Full Text] [Related]
13. Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells.
Warren L; Jardillier JC; Ordentlich P
Cancer Res; 1991 Apr; 51(8):1996-2001. PubMed ID: 1672622
[TBL] [Abstract][Full Text] [Related]
14. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
Zamora JM; Pearce HL; Beck WT
Mol Pharmacol; 1988 Apr; 33(4):454-62. PubMed ID: 3162758
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells.
Danks MK; Metzger DW; Ashmun RA; Beck WT
Cancer Res; 1985 Jul; 45(7):3220-4. PubMed ID: 3891080
[TBL] [Abstract][Full Text] [Related]
16. [In vitro characterization of S9788, a new modulator of multidrug resistance].
Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
18. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells.
Muller C; Goubin F; Ferrandis E; Cornil-Scharwtz I; Bailly JD; Bordier C; Bénard J; Sikic BI; Laurent G
Mol Pharmacol; 1995 Jan; 47(1):51-6. PubMed ID: 7838133
[TBL] [Abstract][Full Text] [Related]
19. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
Tsuruo T
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Berlion M; Arvelo F; Leonce S; Bourgeois Y; Rigaudy P; Bizzari JP; Poupon MF
In Vivo; 1993; 7(5):399-405. PubMed ID: 7906553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
